GONDOLA – 365 days in retrospect
Late 2019 was a proud moment for us at Gondola Medical Technologies. We received a research grant of Euro 2.5 million from Horizon 2020 (EIC Accelerator Award) of the European Commission. This grant is a vote of confidence that helped us boost our activities as a company.
The GONDOLA® AMPS treatment is a non-invasive, no side effects therapy for neurological conditions that cause walking and balance impairments. It helps patients to regain independence, to move better, and live better.
HQ at Biopôle in Lausanne
Moving our HQ from Ticino to Biopôle in Lausanne is strategic for our development as a MedTech company. Biopôle is a top-notch science park, renowned in Switzerland and internationally, and we are proud to be part of its life science community. Over the last year, our team grew from 5 to 17 employees, scaling our scientific research, marketing, and sales activities.
Treatment scope & new markets
Besides the launch of version 3.0 of GONDOLA® device for domestic use, assuring an easier to use version and scalable volumes, we have extended the use of our AMPS treatment from Parkinson’s disease to other neurological disorders such as stroke and cerebral palsy, but also to spinal stroke and other conditions.
The geographical expansion into new markets, namely Germany, France, and Spain, is well underway. At Gondola Medical Technologies, we are looking forward to further growing the GONDOLA® network of Partner Centers in Germany. It is all we can share, for now.
Growth Tech Loan from the FIT
Gondola Medical Technologies received a CHF 500’000 growth tech loan from the FIT (Fondation pour l’innovation technologique) that is based at the EPFL in Lausanne. The loan is coming in two installments; CHF 200’000 upfront, followed by CHF 300’000 based on a milestone plan submitted to the FIT’s selection committee. These funds will be dedicated to research and development, which includes growing the clinical research team and their studies.